DK1749098T3 - Kimære adenoviruser til anvendelse i carcerbehandling - Google Patents

Kimære adenoviruser til anvendelse i carcerbehandling

Info

Publication number
DK1749098T3
DK1749098T3 DK05753804.3T DK05753804T DK1749098T3 DK 1749098 T3 DK1749098 T3 DK 1749098T3 DK 05753804 T DK05753804 T DK 05753804T DK 1749098 T3 DK1749098 T3 DK 1749098T3
Authority
DK
Denmark
Prior art keywords
cancer treatment
chimeric adenoviruses
adenoviruses
chimeric
cancer
Prior art date
Application number
DK05753804.3T
Other languages
English (en)
Inventor
Paul Harden
Terry Hermiston
Irene Kuhn
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Application granted granted Critical
Publication of DK1749098T3 publication Critical patent/DK1749098T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK05753804.3T 2004-05-26 2005-05-24 Kimære adenoviruser til anvendelse i carcerbehandling DK1749098T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57485104P 2004-05-26 2004-05-26
PCT/US2005/018301 WO2005118825A2 (en) 2004-05-26 2005-05-24 Chimeric adenoviruses for use in cancer treatment

Publications (1)

Publication Number Publication Date
DK1749098T3 true DK1749098T3 (da) 2011-04-04

Family

ID=35355425

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05753804.3T DK1749098T3 (da) 2004-05-26 2005-05-24 Kimære adenoviruser til anvendelse i carcerbehandling

Country Status (33)

Country Link
US (6) US7510868B2 (da)
EP (1) EP1749098B1 (da)
JP (1) JP4787936B2 (da)
KR (1) KR101169109B1 (da)
CN (3) CN104263703B9 (da)
AR (2) AR049188A1 (da)
AT (1) ATE491799T1 (da)
AU (1) AU2005250396B2 (da)
BR (2) BRPI0510475B8 (da)
CA (2) CA2836987C (da)
CR (1) CR8794A (da)
DE (1) DE602005025340D1 (da)
DK (1) DK1749098T3 (da)
EC (1) ECSP067088A (da)
ES (1) ES2358204T3 (da)
GT (1) GT200500129A (da)
HK (3) HK1109421A1 (da)
HR (1) HRP20110179T1 (da)
IL (2) IL179098A (da)
MX (1) MXPA06013570A (da)
MY (1) MY140829A (da)
NO (1) NO340708B1 (da)
NZ (1) NZ551443A (da)
PA (1) PA8634201A1 (da)
PE (1) PE20060277A1 (da)
PL (1) PL1749098T3 (da)
PT (1) PT1749098E (da)
RU (1) RU2448157C2 (da)
TW (1) TWI366603B (da)
UA (1) UA89957C2 (da)
UY (1) UY28926A1 (da)
WO (1) WO2005118825A2 (da)
ZA (1) ZA200610763B (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118825A2 (en) 2004-05-26 2005-12-15 Schering Aktiengesellschaft Chimeric adenoviruses for use in cancer treatment
US20070258952A1 (en) * 2006-05-04 2007-11-08 Baylor Research Institute Anti-Tumor Activity of an Oncolytic Adenovirus-Delivered Oncogene siRNA
US20100316609A1 (en) * 2006-10-18 2010-12-16 University Of Rochester Conditionally Replicating Viruses for Cancer Therapy
JP5188504B2 (ja) 2006-11-13 2013-04-24 サンガモ バイオサイエンシズ インコーポレイテッド ヒトグルココルチコイド受容体遺伝子座の修飾のための方法および組成物
CA2673520A1 (en) * 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Generation of oncolytic adenoviruses and uses thereof
KR100856310B1 (ko) 2007-02-28 2008-09-03 삼성전기주식회사 이동통신 단말기
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
SI2825640T1 (sl) 2012-03-12 2016-08-31 Crucell Holland B.V. Šarže rekombinantnega adenovirusa s spremenjenimi konci
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
KR102050616B1 (ko) * 2012-03-22 2019-12-03 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
AU2014222610A1 (en) 2013-02-28 2015-10-15 Psioxus Therapuetics Limited A process for the production of adenovirus
EP2971008B1 (en) 2013-03-14 2018-07-25 Salk Institute for Biological Studies Oncolytic adenovirus compositions
US11173186B2 (en) * 2013-06-14 2021-11-16 Psioxus Therapeutics Limited Dosing regime and formulations for type B adenovirus
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
GB2531821A (en) * 2013-10-25 2016-05-04 Psioxus Therapeutics Ltd Oncolytic adenoviruses armed with heterologous genes
RS57043B1 (sr) * 2013-10-25 2018-05-31 Psioxus Therapeutics Ltd Onkolitički adenovirusi snabdeveni heterologus genima
GB201415579D0 (en) 2014-09-03 2014-10-15 Psioxus Therapeutics Ltd A process
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
GB201406608D0 (en) * 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201510197D0 (en) 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
EP3186366A2 (en) 2014-08-27 2017-07-05 Psioxus Therapeutics Limited A process for the production of adenovirus
BR112017023171A2 (pt) * 2015-04-30 2018-07-17 Psioxus Therapeutics Limited adenovírus oncolítico que codifica proteína b7
EA201891021A1 (ru) 2015-12-17 2018-11-30 Псайоксус Терапьютикс Лимитед Аденовирус группы b, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
EP3487999A4 (en) * 2016-07-25 2020-05-20 Ascend Biopharmaceuticals Ltd METHODS OF TREATING CANCER
EP4273252A3 (en) 2016-08-29 2024-04-17 Akamis Bio Limited Adenovirus armed with bispecific t cell engager (bite)
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
PT3630143T (pt) 2017-06-01 2023-08-29 Akamis Bio Ltd Vírus oncolítico e método
AU2018328223A1 (en) 2017-09-05 2020-03-12 GLAdiator Biosciences, Inc. Delivery of payloads to stem cells
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
EP3906038A4 (en) 2018-11-21 2022-06-01 Mayo Foundation for Medical Education and Research ADENOVIRUS AND METHODS OF USE OF ADENOVIRUS
MX2021010577A (es) 2019-04-29 2021-10-13 Mayo Found Medical Education & Res Compuestos de union a pd-l1 multivalentes para tratar cancer.
GB201909081D0 (en) 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
WO2022170219A1 (en) 2021-02-05 2022-08-11 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
GB202102049D0 (en) 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
HU216871B (hu) 1993-07-13 1999-09-28 Rhone-Poulenc Rorer S.A. Defektív adenovírusvektorok és génterápiai alkalmazásuk
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
US5877011A (en) * 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
CN1242051A (zh) 1996-12-31 2000-01-19 昂尼克斯药物公司 用于肿瘤治疗和预防的致细胞病变病毒
EP1036183B1 (en) 1997-02-20 2007-10-03 The Johns Hopkins University School Of Medicine Mutations in atp-dependent transposition proteins that reduce target-site specificity
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US20020019051A1 (en) 1998-05-27 2002-02-14 Monika Lusky Chimeric adenoviral vectors
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CN1110553C (zh) 1998-07-15 2003-06-04 杭州赛狮生物技术开发有限公司 基因工程腺病毒及其用途
DE60043126D1 (de) * 1999-05-17 2009-11-19 Crucell Holland Bv Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten
EP1083228A1 (en) * 1999-09-10 2001-03-14 Introgene B.V. Modified adenoviral vectors for use in gene therapy
US7396679B2 (en) 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
AU2001265154A1 (en) * 2000-05-31 2001-12-11 Genvec, Inc. Method and composition for targeting an adenoviral vector
WO2002053759A1 (en) * 2001-01-04 2002-07-11 Wadell Goeran Viral vector for gene therapy
US7858367B2 (en) 2002-04-30 2010-12-28 Duke University Viral vectors and methods for producing and using the same
CN1327899C (zh) * 2003-05-10 2007-07-25 彭朝晖 腺病毒载体与p53基因的基因重组体的应用
WO2005118825A2 (en) 2004-05-26 2005-12-15 Schering Aktiengesellschaft Chimeric adenoviruses for use in cancer treatment
US7550296B2 (en) 2004-12-01 2009-06-23 Bayer Schering Pharma Ag Generation of replication competent viruses for therapeutic use
CA2673520A1 (en) 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Generation of oncolytic adenoviruses and uses thereof

Also Published As

Publication number Publication date
HRP20110179T1 (hr) 2011-04-30
JP2008500051A (ja) 2008-01-10
CA2567094C (en) 2014-11-25
CN1997746B (zh) 2012-09-26
CR8794A (es) 2007-08-28
KR101169109B1 (ko) 2012-07-26
ECSP067088A (es) 2007-01-26
NO20066002L (no) 2006-12-22
WO2005118825A3 (en) 2006-11-23
TW200611974A (en) 2006-04-16
UY28926A1 (es) 2006-01-31
ZA200610763B (en) 2009-06-24
NZ551443A (en) 2010-01-29
UA89957C2 (ru) 2010-03-25
US20050265973A1 (en) 2005-12-01
IL226820A0 (en) 2013-07-31
US20130230902A2 (en) 2013-09-05
US20150037874A1 (en) 2015-02-05
AR090647A2 (es) 2014-11-26
CN104263703A (zh) 2015-01-07
NO340708B1 (no) 2017-06-06
CN102816742A (zh) 2012-12-12
US20130217095A1 (en) 2013-08-22
EP1749098A2 (en) 2007-02-07
JP4787936B2 (ja) 2011-10-05
US20130209409A1 (en) 2013-08-15
WO2005118825A2 (en) 2005-12-15
ES2358204T3 (es) 2011-05-06
HK1179655A1 (en) 2013-10-04
BRPI0510475B1 (pt) 2020-09-29
IL179098A0 (en) 2007-03-08
CA2836987C (en) 2016-07-05
US9234185B2 (en) 2016-01-12
CN102816742B (zh) 2014-04-09
EP1749098B1 (en) 2010-12-15
KR20070020302A (ko) 2007-02-20
HK1205529A1 (en) 2015-12-18
US7510868B2 (en) 2009-03-31
IL179098A (en) 2015-09-24
CA2567094A1 (en) 2005-12-15
MXPA06013570A (es) 2007-02-08
US20120231524A1 (en) 2012-09-13
US8765463B2 (en) 2014-07-01
ATE491799T1 (de) 2011-01-15
RU2006145071A (ru) 2008-07-10
PE20060277A1 (es) 2006-05-25
US8158599B2 (en) 2012-04-17
PL1749098T3 (pl) 2011-05-31
CA2836987A1 (en) 2005-12-15
BRPI0510475A (pt) 2007-11-06
GT200500129A (es) 2006-03-23
AR049188A1 (es) 2006-07-05
PT1749098E (pt) 2011-02-02
CN104263703B (zh) 2018-01-09
RU2448157C2 (ru) 2012-04-20
IL226820A (en) 2017-07-31
US9034344B2 (en) 2015-05-19
AU2005250396B2 (en) 2010-11-11
DE602005025340D1 (de) 2011-01-27
US9115337B2 (en) 2015-08-25
BR122013008865B1 (pt) 2020-11-24
CN1997746A (zh) 2007-07-11
AU2005250396A1 (en) 2005-12-15
TWI366603B (en) 2012-06-21
BRPI0510475B8 (pt) 2021-05-25
US20090227000A1 (en) 2009-09-10
CN104263703B9 (zh) 2019-12-17
MY140829A (en) 2010-01-29
HK1109421A1 (en) 2008-06-06
PA8634201A1 (es) 2006-11-09
BR122013008865B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
DK1749098T3 (da) Kimære adenoviruser til anvendelse i carcerbehandling
LTC2100614I2 (lt) Antikūnas prieš PDGFR-alfa, skirtas naudoti auglių gydymui
DK3424932T3 (da) Bronophthalider til terapeutisk anvendelse
DK1960370T3 (da) Pyridazinonderivater til tumorbehandling
SI2358697T1 (sl) Spojine izoindolina za uporabo pri zdravljenju raka
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
DK1827412T3 (da) Sammensætninger til anvendelse i kirurgi
HK1200435A1 (en) Water treatment
DK1863899T3 (da) Hudbehandlingspræparater
DK2101805T3 (da) Integrinligander til anvendelse i behandling af cancer
DK2235002T3 (da) 4-pyridinonforbindelser og anvendelse heraf til behandling af cancer
IL185258A (en) Oligodeoxyribonucleotides for use in the treatment of angiogenesis-dependent tumors in human
PT1830847E (pt) Tratamento para o cancro
DK1803456T5 (da) Farmaceutiske sammensætninger omfattende L-733060 til anvendelse ved behandling af cancertumorer
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
HK1151971A1 (en) Compounds for use in the treatment of cancer
GB0428187D0 (en) Cancer treatment
GB0616013D0 (en) Water treatment
GB0413346D0 (en) Treating cancer
GB0408196D0 (en) Water treatment
GB0507685D0 (en) Cancer treatment
GB0404675D0 (en) Cancer treatment
ZA200804027B (en) Neuroendocrine tumor treatment using m TOR inhibitors
GB0522671D0 (en) Spisulosine compounds for use in cancer therapy